Myelodysplastic syndromes (MDSs) comprise a heterogeneous group of disorders characterized by ineffective hematopoiesis presenting with peripheral cytopenias together with hyperplastic bone marrow. In addition, MDS patients show an increased risk of progression toward acute myeloid leukemia (AML). Although the pathogenetic mechanisms underlying both MDS and de novo AML development have broadly been studied on a genetic level, the molecular factors that determine the progression from MDS to secondary AML (s-AML) are largely unknown. So far, blast counts and cytogenetic abnormalities are known as major determinants of the risk for AML transformation, 1 however, little is known about the molecular genetic events associated with MDS progression to s-AML. De novo AML is characterized by a block in differentiation as well as hyperproliferation and increased survival of a malignant clone, which is due to several genetic alterations. In comparison, the etiology of s-AML can also be regarded as a multistep process wherein similar genes might be involved. These include class I and class II mutations which are involved in signal transduction (for example, FLT3 and NRAS) and transcriptional regulation (for example, RUNX1 and MLL) as well as alterations in NPM1. Recent studies on MDS pathogenesis have reported on widespread regions of uniparental disomy (UPD) across the entire genome with frequent sites of UPD found on chromosomes 1, 4, 6, 7 and 11. 2, 3, 4 Thus UPD may participate in the malignant pathological process and possibly disease progression, as accompanying loss of heterozygosity (LOH) may result in the duplication of a mutant allele located within the affected region. Comparisons of paired patient samples at both the MDS and s-AML stage provide an excellent model for studying the underlying genetic events responsible for the progression from MDS to s-AML. In the present study, we analyzed a total of 38 patients at both states of disease (male/female: 25/13; median age at diagnosis 69.5; range 29.2-82.9), who were referred to the MLL Munich Leukemia Laboratory between August 2005 and August 2009 for diagnostic workup, focusing on cytogenetic anomalies as well as molecular mutations in genes NPM1, MLL, NRAS, RUNX1
and FLT3. Additionally, we performed genome-wide SNP microarray analyses in 34 out of 38 patients at both time points. Mononuclear cells from bone marrow or peripheral blood were used for all cytogenetic, molecular and SNP array experiments.
Diagnosis was performed according to standard WHO (World Health Organization) criteria. 5 Patients gave their informed written consent for this investigation and the study adheres to the rules of the local Internal Review Board and the tenets of the revised Helsinki protocol. At initial MDS diagnosis, patients were classified according to the following WHO categories: RARS (n ¼ 2), RCMD (n ¼ 3), RAEB-1 (n ¼ 11), RAEB-2 (n ¼ 9), MDS unclassifiable (n ¼ 8), CMML (n ¼ 3) and MDS/MPN overlap (n ¼ 2). Progression to s-AML was defined by blasts 420% in bone marrow or peripheral blood. Even though CMML is not classified as MDS according to the new WHO classification, this entity was still included because of the presence of myelodysplastic features and the rather high transformation rate to AML. 5 AML transformation occurred at a median time of 269 days (range 40-1044 days) following initial MDS diagnosis. The high number of RAEB-1 and RAEB-2 patients (20/38; 52.6%) in our cohort reflects the fact that more advanced stages of MDS are particularly prone to s-AML progression.
For detailed evaluation, patients were grouped into three categories: (1) cases with cytogenetic progression (n ¼ 9, 24%) (2) cases with molecular genetic progression (n ¼ 10; 26%) and (3) cases with cytogenetic and molecular genetic progression (n ¼ 4; 11%). In all, 15 patients (39%) showed neither a change in karyotype nor in the molecular marker profile of the analyzed genes. In the total cohort at MDS stage, patients either exhibited a normal karyotype (n ¼ 27; 71%) or showed a single cytogenetic abnormality (n ¼ 8, 21%). One patient had two alterations and two patients displayed a complex aberrant karyotype.
In the course of disease evolution, 9/38 patients (24%, unique patient numbers; UPNs 1-9) showed increased cytogenetic complexity with gains of 1-10 aberrations in comparison to MDS stage (median number of gained anomalies ¼ 1) ( Table 1 , subgroup: cytogenetic progression). Three patients (UPNs 2, 4 and 5) acquired a trisomy 8 which was the only recurrent , À7,der(9)dup(9)(p13p24)t(9;21) (p24;q11)t(7;21)(?;q22), +r(9) ins(9;19)ins(9;21),der(11)del (11) (p13)t(7;11)(?;q14),À13, der (14;15)(q10;q10),der (15) upd (4) Values in bold mark changes that occurred during MDS progression towards s-AML.
n Acute erythroid leukemia (AML M6), erythroid precursors 450% and blasts X20% of non-erythroid cells.
nn Because UPD is a cytogenetic event leading to a molecular genetic alteration, that is, homozygosity of mutated RUNX1, this patient was taken up into the group presenting both cytogenetic and molecular genetic alterations in the progression from MDS to s-AML.
nnn Clonality confirmed by interphase FISH.
Letters to the Editor cytogenetic abnormality gained during disease evolution in our patient cohort. Further chromosomal gains (n ¼ 6), losses (n ¼ 1), insertions (n ¼ 1) and unbalanced translocations (n ¼ 1) were detected individually or in combination. One patient (UPN 6) acquired a balanced t(3;21)(q26;q22) (EVI1-RUNX1) translocation after progression to s-AML, and both patients displaying a complex aberrant karyotype at MDS stage (UPNs 7 and 9) developed an even more complex karyotype after AML transformation. In all, 2 out of 10 patients with cytogenetic progression displayed aberrant molecular markers at the time of MDS diagnosis including RUNX1 (UPN 1) and NRAS codon 61 (UPN 8) mutations. Molecular genetic analysis of RUNX1, FLT3, NRAS, MLL-PTD and NPM1 at MDS stage revealed the presence of MLL-PTDs (n ¼ 2), NRAS (n ¼ 2), NPM1 (n ¼ 1) and RUNX1 (n ¼ 9) mutations ( Figure 1 , part: MDS). As RUNX1 mutations were by far the most frequently occurring mutations, we looked for further genetic markers in this subgroup. Concerning cytogenetics, seven out of nine RUNX1-posititve patients presented a normal karyotype (UPNs 1, 10, 11, 22, 23, 24 and 25), one patient showed a loss of the Y chromosome (UPN 17) and one had an isochromosome 21q (UPN 26). With the exception of an NRAS codon 12 mutation in one patient (UPN 25) and an NPM1 mutation in another (UPN 17), no further mutations were detected. FLT3-ITD mutations were not detected at MDS stage.
After progression to s-AML, 10 out of 38 patients (26%) presented acquired additional molecular genetic markers (Table 1, Four patients (11%) presented both additional cytogenetic and molecular genetic changes during s-AML development (Table 1 , subgroup: cytogenetic and molecular genetic progression, UPNs 20-23). While one patient developed a complex aberrant karyotype along with an NPM1 mutation (UPN 21), another patient showed deletions in the long arms of chromosomes 5 and 7 as well as a RUNX1 mutation in the course of MDS progression (UPN 20). Gain of chromosome 13 and a second RUNX1 mutation were associated with s-AML development in another patient who already presented an independent RUNX1 mutation at MDS stage (UPN 22). The fourth patient (UPN 23) taken up into this group is discussed below because of the patient's association with UPD. In all, 15 patients (39%, UPNs 24-38) regardless of their cytogenetic or molecular genetic status at MDS did not present cytogenetic alterations or mutations in NPM1, MLL, RUNX1 and/or FLT3.
In addition to cytogenetic and molecular genetic analyses, we performed SNP arrays. SNP arrays are a useful technique to identify both cryptic chromosomal imbalances and copy-neutral LOH. As cytogenetic abnormalities are mostly unbalanced in MDS, SNP arrays seemed particularly promising in this disease entity. As compared with chromosome banding analysis, breakpoints of deletions could be refined and mapped more precisely based on SNP array results (cf. Table 1 ). In addition, SNP microarray analyses revealed the presence of UPD in 11 out of 34 paired samples including chromosomal regions 2p (UPN 15), 4q (UPNs 14 and 16), 7q (UPN 2), 11q (UPN 29), 12p (UPN 25), 13q (UPN 8), 17q (UPN 3), 19p (UPN 6), 19q (UPNs 3 and 35) and 21q (UPN 23). While 9 out of these 11 patients showed the same regions of UPD at both their MDS and s-AML stages, one patient acquired UPD(21q) (upd(21)(q11.2-qter)) (UPN 23) and another patient gained both UPD(17q) (upd(17)(q21.2-qter)) and UPD(19q) (upd(19q13.42-qter)) during disease progression (UPN 3). Almost all UPDs found were entirely extended to the telomere, suggesting that they result from a single recombination event on each chromosome. As most regions of UPD were already detected at MDS stage, we cannot exclude germ line origin of SNP-A-detected lesions. Nevertheless, UPD(21q), which was acquired during disease progression, coincided with a shift from heterozygous to a homozygous RUNX1 mutation suggesting a role for acquired UPD as a mechanism leading to copy-neutral LOH of RUNX1 ( Figure 2) . As UPD is a cytogenetic event leading to a molecular genetic alteration, that is, homozygosity of mutated RUNX1, this patient was taken up into the group presenting both cytogenetic and molecular genetic alterations in the progression from MDS to s-AML.
In one patient, UPD(4q) was manifested with a mutation in TET2 (4q24) (UPN 14). This mutation was already present at MDS stage. Mutations in CBL that have been reported to be associated with UPD(11q) 6 could, however, not be detected in our patient presenting UPD(11q) (UPN 29). As results from chromosome banding analysis were available in addition to SNP-array results, we examined the sites of breakage in order to evaluate any differences in cytogenetic breakpoints between MDS and s-AML. Although the extent of deletion did not differ in patients with chromosomal losses, loss of chromosomal material at chromosomal breakpoints was observed in the patient who acquired an insertion(7;X) in the course of AML evolution (UPN 8). Interestingly, the deletions included genes IKZF1, DDC, GRB10 and COBL on 7p12.1-12.2, BCOR on Xp11.4 and CDKL5 and PPEF1 on Xp22.13 (supplementary Figure 1) .
Of those patients presenting with neither cytogenetic nor molecular alterations at initial MDS diagnosis (n ¼ 20), five patients gained cytogenetic aberrations (UPNs 2-6), two acquired RUNX1 mutations (UPNs 13 and 14), two gained mutations in NPM1 (UPNs 15 and 16) and one patient obtained Letters to the Editor an NRAS codon 12 mutation (UPN 12). Moreover, one patient gained a RUNX1 mutation in conjunction with deletions in the long arms of both 5q and 7q (UPN 20) and a further patient acquired an NPM1 mutation along with a complex aberrant karyotype (UPN 21). No cytogenetic or molecular genetic alterations were detectable in the remaining eight patients both at MDS and s-AML stage.
As RUNX1 mutations were observed at a high frequency of 24% at MDS stage, we investigated progression markers in this group of patients. With regard to progression markers in all RUNX1-mutated MDS patients (n ¼ 9), one patient showed increased cytogenetic complexity (UPN 1), two gained FLT3-ITDs (UPNs 10 and 17), one acquired MLL-PTDs (UPN 11), one shifted from heterozygously to homozygously mutated RUNX1 (UPN 23) and three patients did not show additional alterations (UPNs 24-26). However, one patient of the latter group had already presented an additional NRAS codon 12 mutation at initial MDS diagnosis. One patient developed a second RUNX1 mutation along with trisomy 13 (UPN 22). Interestingly, both patients who gained a chromosome 13 (UPNs 1 and 22) had antecedent mutations in RUNX1. According to current literature, RUNX1 mutations occur at a frequency of about 15% in MDS, 7 thus the rate of RUNX1 mutations is increased in our patient cohort, which is defined by leukemic evolution. Thus, our results suggest that the detection of RUNX1 mutations in MDS comes along with a propensity to leukemic transformation. FLT3-ITDs occurred only after progression to s-AML in our cohort. Both patients who gained FLT3-ITDs in the progression from MDS to s-AML presented antecedent mutations in RUNX1. These two patients fit nicely into the two-hit hypothesis for the pathogenesis of AML with RUNX1 mutations altering gene expression (type I mutation) and FLT3-ITDs leading to enhanced proliferation (type II mutation). 8 In the present study, RUNX1, a known cancer gene, is located in a region affected by UPD. In this patient, a heterozygous RUNX1 mutation has been found at MDS diagnosis. LOH of the remaining healthy RUNX1 allele due to UPD was accompanied by progression to s-AML within less than 6 months after initial MDS diagnosis. The contribution of UPD to s-AML evolution sheds light on a novel aspect regarding the progression from MDS to s-AML. The second genetic hit is neither an additional mutation nor a cytogenetic alteration but rather the duplication of a RUNX1-mutated allele leading to LOH of the unaffected allele.
From a genetic point of view, MDS and AML show an overlapping pattern of cytogenetic and molecular genetic abnormalities. With the exception of AML-specific recurrent balanced rearrangement, mostly unbalanced abnormalities occur both in MDS and AML.
In conclusion, our data demonstrate that 60% (23/38) of patients acquired additional genetic abnormalities during progression from MDS to s-AML. One group (24%) preferentially gained additional chromosome abnormalities while the other group (26%) was characterized by additional molecular mutations. Four patients (11%) presented both additional cytogenetic and molecular genetic changes, one of which acquired UPD(21q) with RUNX1-LOH in the course of s-AML development. While RUNX1 mutations already occurred at a high frequency at MDS stage, mutations in FLT3 were seen only after progression to s-AML.
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